Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials.

Cell Rep MedAug 13, 2026 (epub)
Clinical ResearchPulmonology

Yong-Hua Gao, Xue-Shan Li, Xiao-Li Sun et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of two randomized trials (SAVE-BE and TORNASOL) evaluated the impact of baseline symptom burden on treatment responses to florensocatib and inhaled tobramycin in patients with bronchiectasis. Florensocatib significantly reduced exacerbation rates (RR, 0.47) but did not improve symptoms, while tobramycin improved quality of life in high-symptom patients, suggesting that symptom burden may guide treatment strategies.

Key findings

  • Florensocatib reduced exacerbation rates versus placebo (RR, 0.47; 95% CI, 0.33-0.67; p < 0.0001).
  • In high-symptom patients, tobramycin improved QoL-B-RSS by exceeding the 8-point cutoff.
  • Greater benefits from tobramycin were observed in patients with higher baseline symptom burden.

Why it matters

Understanding how baseline symptom burden influences treatment response can help clinicians tailor therapies for bronchiectasis, potentially improving patient outcomes through personalized treatment strategies.

Source

PubMed · PMID 42594878

Published in Cell Rep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.